基于八种胰岛素抵抗替代指数预测 中国中老年糖尿病人群肝病 发病风险——一项基于CHARLS的队列研究
Assessment of Eight Insulin Resistance Surrogate Indexes for Predicting Liver Disease Incidence in Chinese Middle-Aged and Elderly Populations with Diabetes—A Cohort Study Based on CHARLS
DOI: 10.12677/acm.2026.1641321, PDF,   
作者: 陈雨星, 胡 鹏*:重庆医科大学附属第二医院感染病科,感染性疾病分子生物学教育部重点实验室,重庆医科大学病毒性肝炎研究所,重庆
关键词: 胰岛素抵抗替代指数肝脏疾病糖尿病中老年人Insulin Resistance Surrogate Index Liver Disease Diabetes Middle-Aged and Older Adults
摘要: 背景:本研究旨在探讨八种胰岛素抵抗替代指数,包括eGDR、METS-IR、TyG指数及其变体(TyG-BMI、TyG-WHtR、TyG-WC、TyG-CVAI和CTI),与糖尿病患者肝脏疾病风险之间的关系。研究旨在评估并比较这些指数对肝脏疾病风险的预测能力,以弥补当前该领域比较性研究的不足。方法:本研究分析了中国健康与养老追踪调查(CHARLS)的数据。采用多变量Cox比例风险回归模型分析胰岛素抵抗替代指数与肝脏疾病风险的关系。通过限制性立方样条图探索胰岛素抵抗替代指数与肝脏疾病风险之间的剂量–反应关系。利用受试者工作特征曲线分析计算各胰岛素抵抗替代指数的曲线下面积。结果:在调整混杂因素后,eGDR每增加一个单位与肝脏疾病风险降低相关(调整后HR:0.418,95% CI:0.222~0.787,P = 0.007)。相反,METS-IR、CTI、TyG、TyG-BMI、TyG-WHtR、TyG-WC和TyG-CVAI的增加则与较高的肝脏疾病风险相关,其调整后HR (95% CI)分别为1.271 (1.047~1.542)、1.345 (1.077~1.679)、1.353 (1.105~1.657)、1.337 (1.114~1.606)、1.400 (1.104~1.776)、1.652 (1.278~2.136)和1.534 (1.196~1.968)。剂量–反应分析显示,这八种胰岛素抵抗替代指数与肝脏疾病风险之间存在线性关系。ROC分析表明,在糖尿病人群中,TyG-WC对肝脏疾病的预测价值最高(AUC: 0.651)。结论:这八种胰岛素抵抗替代指数与糖尿病患者发生肝脏疾病的高风险相关。其中,TyG-WC在预测中国中老年糖尿病人群肝脏疾病风险方面表现出中等水平的预测能力。
Abstract: Background: This study examined the relationships between eight insulin resistance (IR) surrogate indexes, including eGDR, METS-IR, TyG index and its variants (TyG-BMI, TyG-WHtR, TyG-WC, TyG-CVAI, and CTI), and liver disease risk in individuals with diabetes. It aimed to assess and compare the predictive abilities of these indexes for liver disease risk, addressing the current lack of comparative studies in this area. Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS) were analyzed in this study. Multivariate Cox regression models were applied to analyse the relationships of IR surrogate indexes with liver disease risk. The dose-response relationships between IR surrogate indexes and liver disease risk were explored using restricted cubic splines. The areas under the curve (AUCs) of IR surrogate indexes were calculated by receiver operating characteristic (ROC) analysis. Results: After adjusting for confounders, a unit increase in eGDR was linked to a lower risk of liver disease (adjusted HR: 0.418, 95% CI: 0.222~0.787, P = 0.007). Conversely, increases in METS-IR, CTI, TyG, TyG-BMI, TyG-WHtR, TyG-WC, and TyG-CVAI were linked to higher liver disease risk, with adjusted HRs (95% CIs) of 1.271 (1.047~1.542), 1.345 (1.077~1.679), 1.353 (1.105~1.657), 1.337 (1.114~1.606), 1.400 (1.104~1.776), 1.652 (1.278~2.136), and 1.534 (1.196~1.968), respectively. Dose-response analyses indicated a linear relationship between eight IR surrogate indexes and liver disease risk. ROC analysis showed TyG-WC had the highest predictive value for liver disease in diabetics (AUC: 0.651). Conclusion: The eight IR surrogate indexes were associated with high risk of liver disease in individuals with diabetes. Among these, TyG-WC demonstrated a moderate predictive ability for liver disease risk in Chinese middle-aged and elderly populations with diabetes.
文章引用:陈雨星, 胡鹏. 基于八种胰岛素抵抗替代指数预测 中国中老年糖尿病人群肝病 发病风险——一项基于CHARLS的队列研究[J]. 临床医学进展, 2026, 16(4): 902-914. https://doi.org/10.12677/acm.2026.1641321

参考文献

[1] Asrani, S.K., Devarbhavi, H., Eaton, J. and Kamath, P.S. (2019) Burden of Liver Diseases in the World. Journal of Hepatology, 70, 151-171. [Google Scholar] [CrossRef] [PubMed]
[2] Alqahtani, S.A., Chan, W. and Yu, M. (2023) Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma. Clinics in Liver Disease, 27, 211-223. [Google Scholar] [CrossRef] [PubMed]
[3] Pereira, F., Azevedo, R., Linhares, M., Pinto, J., Leitão, C., Caldeira, A., et al. (2020) Hepatic Osteodystrophy in Cirrhosis Due to Alcohol-Related Liver Disease. Revista Española de Enfermedades Digestivas, 113, 563-569. [Google Scholar] [CrossRef] [PubMed]
[4] Colantoni, A., Bucci, T., Cocomello, N., Angelico, F., Ettorre, E., Pastori, D., et al. (2024) Lipid-Based Insulin-Resistance Markers Predict Cardiovascular Events in Metabolic Dysfunction Associated Steatotic Liver Disease. Cardiovascular Diabetology, 23, Article No. 175. [Google Scholar] [CrossRef] [PubMed]
[5] Mastrototaro, L. and Roden, M. (2021) Insulin Resistance and Insulin Sensitizing Agents. Metabolism, 125, Article 154892. [Google Scholar] [CrossRef] [PubMed]
[6] Khalid, M., Alkaabi, J., Khan, M.A.B. and Adem, A. (2021) Insulin Signal Transduction Perturbations in Insulin Resistance. International Journal of Molecular Sciences, 22, Article 8590. [Google Scholar] [CrossRef] [PubMed]
[7] Ding, C., Ng Fat, L., Britton, A., Im, P.K., Lin, K., Topiwala, A., et al. (2023) Binge-Pattern Alcohol Consumption and Genetic Risk as Determinants of Alcohol-Related Liver Disease. Nature Communications, 14, Article No. 8041. [Google Scholar] [CrossRef] [PubMed]
[8] DeFronzo, R.A., Tobin, J.D. and Andres, R. (1979) Glucose Clamp Technique: A Method for Quantifying Insulin Secretion and Resistance. American Journal of Physiology-Endocrinology and Metabolism, 237, E214-E223. [Google Scholar] [CrossRef] [PubMed]
[9] Saei Ghare Naz, M., Mousavi, M., Firouzi, F., Momenan, A.A., Azizi, F. and Ramezani Tehrani, F. (2024) Association between Insulin Resistance Indices and Liver Function Parameters among Women with Polycystic Ovary Syndrome. Endocrinology, Diabetes & Metabolism, 7, e490. [Google Scholar] [CrossRef] [PubMed]
[10] Fan, Z., Yang, C., Zhao, X. and Zhang, J. (2025) Association of Cardiometabolic Markers with Hepatic Steatosis and Liver Fibrosis in Population without Obesity and Diabetes. Scientific Reports, 15, Article No. 15695. [Google Scholar] [CrossRef] [PubMed]
[11] Kuo, T., Lu, Y., Yang, C., Wang, B., Chen, L. and Su, C. (2024) Association of Insulin Resistance Indicators with Hepatic Steatosis and Fibrosis in Patients with Metabolic Syndrome. BMC Gastroenterology, 24, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
[12] Nádasdi, Á., Gál, V., Masszi, T., Somogyi, A. and Firneisz, G. (2023) PNPLA3 Rs738409 Risk Genotype Decouples Tyg Index from HOMA2-IR and Intrahepatic Lipid Content. Cardiovascular Diabetology, 22, Article No. 64. [Google Scholar] [CrossRef] [PubMed]
[13] Zhao, X., An, X., Yang, C., Sun, W., Ji, H. and Lian, F. (2023) The Crucial Role and Mechanism of Insulin Resistance in Metabolic Disease. Frontiers in Endocrinology, 14, Article ID: 1149239. [Google Scholar] [CrossRef] [PubMed]
[14] Zeng, P., Cai, X., Yu, X. and Gong, L. (2023) Markers of Insulin Resistance Associated with Non-Alcoholic Fatty Liver Disease in Non-Diabetic Population. Scientific Reports, 13, Article No. 20470. [Google Scholar] [CrossRef] [PubMed]
[15] Yu, X., Chao, J., Wang, X., Dun, S., Song, H., Guo, Y., et al. (2025) Sarcopenic Obesity and the Risk of Atrial Fibrillation in Non-Diabetic Older Adults: A Prospective Cohort Study. Clinical Nutrition, 47, 282-290. [Google Scholar] [CrossRef] [PubMed]
[16] Vergani, M., Borella, N.D., Rizzo, M., Conti, M., Perra, S., Bianconi, E., et al. (2025) Metabolic Dysfunction‐Associated Steatotic Liver Disease, Insulin Sensitivity and Continuous Glucose Monitoring Metrics in Patients with Type 1 Diabetes: A Multi‐Centre Cross‐Sectional Study. Diabetes, Obesity and Metabolism, 27, 3201-3211. [Google Scholar] [CrossRef] [PubMed]
[17] Peng, W., Li, Z. and Fu, N. (2025) Association between eGDR and MASLD and Liver Fibrosis: A Cross-Sectional Study Based on NHANES 2017-2023. Frontiers in Medicine, 12, Article ID: 1579879. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, Y., Lin, H., Jiang, L., Shang, Q., Yin, L., Lin, J.D., et al. (2020) Hepatic Slug Epigenetically Promotes Liver Lipogenesis, Fatty Liver Disease, and Type 2 Diabetes. Journal of Clinical Investigation, 130, 2992-3004. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, D., Lv, X., Li, W., Dai, H., Tan, Y., Yang, D., et al. (2025) Association between Estimated Glucose Disposal Rate and Metabolic Dysfunction-Associated Steatotic Liver Disease and Dyslipidemia in US Adults: A Cross-Sectional Study. Frontiers in Nutrition, 12, Article ID: 1621074. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, R., Liu, R., Liu, M., Tian, Y., Liu, J., Wang, Y., et al. (2025) The Inflammatory Index and Cytokines Are Associated with Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus. Frontiers in Medicine, 12, Article ID: 1659998. [Google Scholar] [CrossRef
[21] Cao, T., Zhu, Q., Tong, C., Halengbieke, A., Ni, X., Tang, J., et al. (2024) Establishment of a Machine Learning Predictive Model for Non-Alcoholic Fatty Liver Disease: A Longitudinal Cohort Study. Nutrition, Metabolism and Cardiovascular Diseases, 34, 1456-1466. [Google Scholar] [CrossRef] [PubMed]
[22] Zhao, Y., Hu, D., Cheng, J., Cao, H., Wang, X., He, J., et al. (2025) Personalized MASLD and Liver Fibrosis Risk Assessment for Adults: Glycemic Status Determines Optimal Choice of Non-Invasive Indices. Diabetology & Metabolic Syndrome, 17, Article No. 461. [Google Scholar] [CrossRef
[23] Han, A.L., Lee, H.K. and Shin, S.R. (2024) Diagnostic Performance of Insulin Resistance Indices for Identifying Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 22, 402-409. [Google Scholar] [CrossRef] [PubMed]
[24] Yang, B., Gong, M., Zhu, X., Luo, Y., Li, R., Meng, H., et al. (2025) Correlation between Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Insulin Resistance Indicators: A Cross-Sectional Study from NHANES 2017-2020. Frontiers in Endocrinology, 16, Article ID: 1514093. [Google Scholar] [CrossRef] [PubMed]
[25] Zhang, Y., Wu, J., Li, T., Qu, Y. and Wang, Y. (2025) Association of Triglyceride-Glucose Related Indices with Mortality among Individuals with MASLD Combined with Prediabetes or Diabetes. Cardiovascular Diabetology, 24, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[26] Grzelka-Woźniak, A., Uruska, A., Szymańska-Garbacz, E., Araszkiewicz, A., Jabłkowski, M., Czupryniak, L., et al. (2023) Indirect Insulin Resistance Markers in Relation to Nonalcoholic Fatty Liver Disease among Patients with Type 1 Diabetes Mellitus. Authors’ Reply. Polish Archives of Internal Medicine, 133, Article No. 16406. [Google Scholar] [CrossRef] [PubMed]
[27] Semmler, G., Balcar, L., Wernly, S., Völkerer, A., Semmler, L., Hauptmann, L., et al. (2023) Insulin Resistance and Central Obesity Determine Hepatic Steatosis and Explain Cardiovascular Risk in Steatotic Liver Disease. Frontiers in Endocrinology, 14, Article ID: 1244405. [Google Scholar] [CrossRef] [PubMed]
[28] Megalaa, M.H., Zeid, A., Zietoun, M., Salem, D.M. and Elrahmany, S.M. (2025) Triglyceride Glucose Index and Related Parameters Are Effective Biomarkers to Identify Metabolic Dysfunction-Associated Steatotic Liver Disease among Egyptian Adults with Type 2 Diabetes. Metabolic Syndrome and Related Disorders, 23, 394-404. [Google Scholar] [CrossRef